Associated Genetic Biomarkers
NCI Definition: A rare, highly aggressive and lethal carcinoma that affects children and young adults. It arises from midline epithelial structures, most commonly the head, neck, and mediastinum. It is a poorly differentiated carcinoma and is characterized by mutations and rearrangement of the NUT gene. A balanced translocation t(15;19) is present that results in the creation of a fusion gene involving the NUT gene, most commonly BRD4-NUT fusion gene. 
NUT carcinomas most frequently harbor alterations in NUTM1, EP300, BRD4, TMPRSS2, and RFWD2 .
NUTM1 Fusion, NUTM1-BRD4 Fusion, BRD4-NUTM1 Fusion, BRD4 Fusion, and TMPRSS2-KLF4 Fusion are the most common alterations in NUT carcinoma .
There is 1 clinical trial for NUT carcinoma, of which 0 are open and 1 is completed or closed. Of the trial that contains NUT carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (0 open).
NUTM1 is the most frequent gene inclusion criterion for NUT carcinoma clinical trials .
Cisplatin, etoposide, and molibresib are the most common interventions in NUT carcinoma clinical trials.
Significant Genes in NUT Carcinoma
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.